FindTrial
Sign In

antithymocyte globulin (rabbit)

DRUG3 trials

Sponsors

St. Jude Children's Research Hospital, Memorial Sloan Kettering Cancer Center, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Acute Lymphoblastic LeukemiaAcute Myelocytic LeukemiaChronic Myelocytic LeukemiaHodgkin or Non-Hodgkin LymphomaJuvenile Myelomonocytic LeukemiaKidney Transplant RecipientsLiving-Donor Kidney TransplantMyelodysplastic Syndrome

Phase 1

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
Active, not recruitingNCT03531736
Memorial Sloan Kettering Cancer CenterMyeloid Diseases
Start: 2018-05-09End: 2027-05-01Updated: 2026-07-24
Treg Modulation With CD28 and IL-6 Receptor Antagonists
CompletedNCT04066114
National Institute of Allergy and Infectious Diseases (NIAID)Kidney Transplant Recipients, Living-Donor Kidney Transplant
Start: 2019-12-11End: 2023-09-14Updated: 2024-10-09

Phase 2

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
TerminatedNCT01621477
St. Jude Children's Research HospitalAcute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia +4
Start: 2012-08-31End: 2015-12-31Updated: 2017-02-20

Related Papers

Regulatory T cell modulation with selective CD28 blockade and IL-6 receptor antagonist in kidney transplant recipients: results of CTOT-24, a prospective clinical trial.
2026-07-22
Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies
Blood2024-11-05